Tertiary lymphoid structures and B lymphocytes: a promising therapeutic strategy to fight cancer

Tertiary lymphoid structures (TLSs) are clusters of lymphoid cells with an organization that resembles that of secondary lymphoid organs. Both structures share common developmental characteristics, although TLSs usually appear in chronically inflamed non-lymphoid tissues, such as tumors. TLSs contain diverse types of immune cells, with varying degrees of spatial organization that represent different stages of maturation. These structures support both humoral and cellular immune responses, thus the correlation between the existence of TLS and clinical outcomes in cancer patients has been extensively studied. The finding that TLSs are associated with better prognosis in some types of cancer has led to the design of therapeutic strategies based on promoting the formation of these structures. Agents such as chemokines, cytokines, antibodies and cancer vaccines have been used in combination with traditional antitumor treatments to enhance TLS generation, with good results. The induction of TLS formation therefore represents a novel and promising avenue for the treatment of a number of tumor types.

[1]  B. Nelson,et al.  B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity. , 2023, Cancer cell.

[2]  F. Wei,et al.  Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC) , 2022, Cell Death & Disease.

[3]  D. Kreisel,et al.  Role of tertiary lymphoid organs in the regulation of immune responses in the periphery , 2022, Cellular and Molecular Life Sciences.

[4]  J. Blay,et al.  Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort , 2022, Nature Medicine.

[5]  Jie Liu,et al.  The Presence of Tertiary Lymphoid Structures Provides New Insight Into the Clinicopathological Features and Prognosis of Patients With Breast Cancer , 2022, Frontiers in Immunology.

[6]  C. Sautès-Fridman,et al.  B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome , 2022, Nature Reviews Clinical Oncology.

[7]  M. Feinmesser,et al.  Tumor-reactive antibodies evolve from non-binding and autoreactive precursors , 2022, Cell.

[8]  P. Laurent-Puig,et al.  Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. , 2022, Immunity.

[9]  T. Schumacher,et al.  Tertiary lymphoid structures in cancer , 2022, Science.

[10]  J. Yun,et al.  Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. , 2021, Journal of hepatology.

[11]  Trevor J Pugh,et al.  Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity , 2021, Nature Communications.

[12]  D. Larsimont,et al.  Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity. , 2021, The Journal of clinical investigation.

[13]  V. Iyer,et al.  IgG Immune Complexes Inhibit Naïve T Cell Proliferation and Suppress Effector Function in Cytotoxic T Cells , 2021, Frontiers in Immunology.

[14]  I. Soubeyran,et al.  Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression , 2021, Nature Cancer.

[15]  G. Tse,et al.  Tumor Microenvironment in Breast Cancer—Updates on Therapeutic Implications and Pathologic Assessment , 2021, Cancers.

[16]  K. Mertz,et al.  A Standardized Analysis of Tertiary Lymphoid Structures in Human Melanoma: Disease Progression- and Tumor Site-Associated Changes With Germinal Center Alteration , 2021, Frontiers in Immunology.

[17]  F. Barone,et al.  Stromal cells in tertiary lymphoid structures: Architects of autoimmunity , 2021, Immunological reviews.

[18]  Hong Wu,et al.  Peritumoral Tertiary Lymphoid Structures Correlate With Protective Immunity and Improved Prognosis in Patients With Hepatocellular Carcinoma , 2021, Frontiers in Immunology.

[19]  T. Cai,et al.  Atlas of breast cancer infiltrated B-lymphocytes revealed by paired single-cell RNA-sequencing and antigen receptor profiling , 2021, Nature Communications.

[20]  N. Girard,et al.  Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients , 2021, Frontiers in Immunology.

[21]  A. Chinnaiyan,et al.  Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes , 2021, Nature Communications.

[22]  Chandler D. Gatenbee,et al.  IgA transcytosis and antigen recognition govern ovarian cancer immunity , 2021, Nature.

[23]  C. Sautès-Fridman,et al.  B cells and cancer: To B or not to B? , 2020, The Journal of experimental medicine.

[24]  Nikhil S. Joshi,et al.  Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses , 2021, Cell.

[25]  S. A. van de Pavert.  Lymphoid Tissue inducer (LTi) cell ontogeny and functioning in embryo and adult , 2020, Biomedical journal.

[26]  C. Sautès-Fridman,et al.  Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer. , 2020, Seminars in immunology.

[27]  S. Ramesh,et al.  Fundamental Concepts of Hydrogels: Synthesis, Properties, and Their Applications , 2020, Polymers.

[28]  P. Sharma,et al.  Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma , 2020, Nature Medicine.

[29]  H. G. van der Poel,et al.  Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial , 2020, Nature Medicine.

[30]  Taheri Fatemeh,et al.  Frequency of IL-10+CD19+ B cells in patients with prostate cancer compared to patients with benign prostatic hyperplasia , 2020, African health sciences.

[31]  E. Barreiro,et al.  B Cells and Tertiary Lymphoid Structures Influence Survival in Lung Cancer Patients with Resectable Tumors , 2020, Cancers.

[32]  A. Ramiro,et al.  A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy , 2020, Journal for ImmunoTherapy of Cancer.

[33]  Chi Zhang,et al.  Single-cell transcriptome and antigen-immunoglobin analysis reveals the diversity of B cells in non-small cell lung cancer , 2020, Genome Biology.

[34]  D. Fernández,et al.  TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy , 2020, Frontiers in Immunology.

[35]  G. Nowicka,et al.  Communication in the Cancer Microenvironment as a Target for Therapeutic Interventions , 2020, Cancers.

[36]  E. Montgomery,et al.  The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures , 2020, Clinical Cancer Research.

[37]  Y. Kawasawa,et al.  Gut-resident CX3CR1hi macrophages induce tertiary lymphoid structures and IgA response in situ , 2020, Science Immunology.

[38]  E. Song,et al.  Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity , 2020, Cell.

[39]  J. Hamzah,et al.  Remodeling of Metastatic Vasculature Reduces Lung Colonization and Sensitizes Overt Metastases to Immunotherapy. , 2020, Cell reports.

[40]  Jian Huang,et al.  Tumour-Infiltrating Immune Cell-Based Subtyping and Signature Gene Analysis in Breast Cancer Based on Gene Expression Profiles , 2020, Journal of Cancer.

[41]  Jeffrey E. Lee,et al.  B cells and tertiary lymphoid structures promote immunotherapy response , 2020, Nature.

[42]  J. Wargo,et al.  B cells are associated with survival and immunotherapy response in sarcoma , 2020, Nature.

[43]  D. Schadendorf,et al.  Tertiary lymphoid structures improve immunotherapy and survival in melanoma , 2020, Nature.

[44]  Yingyong Hou,et al.  Tumor-associated tertiary lymphoid structure predicts postoperative outcomes in patients with primary gastrointestinal stromal tumors , 2020, Oncoimmunology.

[45]  David L. Marron,et al.  B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer , 2019, Cell.

[46]  D. Larsimont,et al.  Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer. , 2019, JCI insight.

[47]  P. Validire,et al.  Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth , 2019, Cancer Immunology Research.

[48]  C. Sautès-Fridman,et al.  Tertiary lymphoid structures in the era of cancer immunotherapy , 2019, Nature Reviews Cancer.

[49]  J. Vacher,et al.  TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion , 2019, Proceedings of the National Academy of Sciences.

[50]  A. Luciani,et al.  Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. , 2019, Journal of hepatology.

[51]  Johannes Griss,et al.  B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma , 2019, Nature Communications.

[52]  D. Larsimont,et al.  Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced in situ by Tumor-Infiltrating B Cells in Breast Cancer , 2018, Front. Immunol..

[53]  T. Zander,et al.  B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies , 2018, Oncoimmunology.

[54]  C. Sautès-Fridman,et al.  Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer , 2018, Cancer Immunology, Immunotherapy.

[55]  Y. Nakatani,et al.  Coexistence of regulatory B cells and regulatory T cells in tumor-infiltrating lymphocyte aggregates is a prognostic factor in patients with breast cancer , 2018, Breast Cancer.

[56]  F. Barone,et al.  Tertiary Lymphoid Structures: Autoimmunity Goes Local , 2018, Front. Immunol..

[57]  V. Velculescu,et al.  Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  J. Bourhis,et al.  Cellular Composition and Contribution of Tertiary Lymphoid Structures to Tumor Immune Infiltration and Modulation by Radiation Therapy , 2018, Front. Oncol..

[59]  G. Bergers,et al.  Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules , 2018, The Journal of pathology.

[60]  G. Bakland,et al.  Mesenchymal stem cells and T cells in the formation of Tertiary Lymphoid Structures in Lupus Nephritis , 2018, Scientific Reports.

[61]  B. Jenkins,et al.  Hyperactive gp130/STAT3‐driven gastric tumourigenesis promotes submucosal tertiary lymphoid structure development , 2018, International journal of cancer.

[62]  S. Steigen,et al.  Presence of high-endothelial venules correlates with a favorable immune microenvironment in oral squamous cell carcinoma , 2018, Modern Pathology.

[63]  A. Gallimore,et al.  Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease? , 2017, Front. Immunol..

[64]  R. Stupp,et al.  Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer , 2017, Oncoimmunology.

[65]  Rohit Loomba,et al.  Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity , 2017, Nature.

[66]  R. Birge,et al.  Efferocytosis of dying cells differentially modulate immunological outcomes in tumor microenvironment , 2017, Immunological reviews.

[67]  Xun Sun,et al.  Rational design of Polymeric Hybrid Micelles to Overcome Lymphatic and Intracellular Delivery Barriers in Cancer Immunotherapy , 2017, Theranostics.

[68]  R. Ganss,et al.  De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors , 2017, Nature Immunology.

[69]  S. Berrih-Aknin,et al.  Use of Toll-Like Receptor Agonists to Induce Ectopic Lymphoid Structures in Myasthenia Gravis Mouse Models , 2017, Front. Immunol..

[70]  S. Wienert,et al.  T Cell Zone Resident Macrophages Silently Dispose of Apoptotic Cells in the Lymph Node , 2017, Immunity.

[71]  Simon C Watkins,et al.  Tbet and IL-36γ cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment , 2017, Oncoimmunology.

[72]  J. Rangel-Moreno,et al.  A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression , 2017, Front. Immunol..

[73]  F. Marincola,et al.  Phase I Trial of Intratumoral Injection of CCL21 Gene–Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration , 2017, Clinical Cancer Research.

[74]  A. Alase,et al.  IL‐36γ has proinflammatory effects on human endothelial cells , 2017, Experimental dermatology.

[75]  D. Hanahan,et al.  Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation , 2017, Science Translational Medicine.

[76]  J. Kolls,et al.  Pneumocystis-Driven Inducible Bronchus-Associated Lymphoid Tissue Formation Requires Th2 and Th17 Immunity. , 2017, Cell Reports.

[77]  Ashutosh Kumar Singh,et al.  Immuno-engineered organoids for regulating the kinetics of B-cell development and antibody production , 2016, Nature Protocols.

[78]  C. Buckley,et al.  Stromal Fibroblasts in Tertiary Lymphoid Structures: A Novel Target in Chronic Inflammation , 2016, Front. Immunol..

[79]  C. Sautès-Fridman,et al.  Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention , 2016, Front. Immunol..

[80]  Yuka Kobayashi,et al.  Gel-Trapped Lymphorganogenic Chemokines Trigger Artificial Tertiary Lymphoid Organs and Mount Adaptive Immune Responses In Vivo , 2016, Front. Immunol..

[81]  H. Hammad,et al.  Early IL-1 Signaling Promotes iBALT Induction after Influenza Virus Infection , 2016, Front. Immunol..

[82]  Yifan Ma,et al.  Integrated Nanovaccine with MicroRNA-148a Inhibition Reprograms Tumor-Associated Dendritic Cells by Modulating miR-148a/DNMT1/SOCS1 Axis , 2016, The Journal of Immunology.

[83]  L. Bixby,et al.  A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases , 2016, Clinical Cancer Research.

[84]  C. Sautès-Fridman,et al.  Tertiary lymphoid structures, drivers of the anti‐tumor responses in human cancers , 2016, Immunological reviews.

[85]  Huiyuan Zhang,et al.  Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients , 2016, Tumor Biology.

[86]  Y. Nagasaki,et al.  Development of a long-acting, protein-loaded, redox-active, injectable gel formed by a polyion complex for local protein therapeutics. , 2016, Biomaterials.

[87]  Xiaoxiao Wang,et al.  Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. , 2016, Cancer cell.

[88]  C. Tripodo,et al.  C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation , 2016, Nature Communications.

[89]  S. Zelenay,et al.  Reducing prostaglandin E2 production to raise cancer immunogenicity , 2016, Oncoimmunology.

[90]  M. Garnelo,et al.  Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma , 2015, Gut.

[91]  K. Rajewsky,et al.  Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma , 2015, Nature Immunology.

[92]  Lisong Shen,et al.  CD19+CD24hiCD38hiBregs involved in downregulate helper T cells and upregulate regulatory T cells in gastric cancer , 2015, Oncotarget.

[93]  Erik Sahai,et al.  Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity , 2015, Cell.

[94]  Nikhil S. Joshi,et al.  Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. , 2015, Immunity.

[95]  Y. Kanai,et al.  Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer , 2015, British Journal of Cancer.

[96]  Geraint T. Williams,et al.  High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression , 2015, Oncoimmunology.

[97]  R. Hruban,et al.  Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation , 2014, Cancer Immunology Research.

[98]  P. Validire,et al.  Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. , 2014, American journal of respiratory and critical care medicine.

[99]  J. Michel,et al.  M1 macrophages act as LTβR-independent lymphoid tissue inducer cells during atherosclerosis-related lymphoid neogenesis. , 2014, Cardiovascular research.

[100]  Pierre Validire,et al.  Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. , 2014, Cancer research.

[101]  C. Desmarais,et al.  Intramuscular Therapeutic Vaccination Targeting HPV16 Induces T Cell Responses That Localize in Mucosal Lesions , 2014, Science Translational Medicine.

[102]  M. Linnebacher,et al.  Combinations of TLR Ligands: A Promising Approach in Cancer Immunotherapy , 2013, Clinical & developmental immunology.

[103]  M. Yeager,et al.  Bronchus-associated lymphoid tissue in pulmonary hypertension produces pathologic autoantibodies. , 2013, American journal of respiratory and critical care medicine.

[104]  R. de Cabo,et al.  Inhibition of Breast Cancer Metastasis by Resveratrol-Mediated Inactivation of Tumor-Evoked Regulatory B Cells , 2013, The Journal of Immunology.

[105]  A. Yoshizawa,et al.  Stromal plasma cells expressing immunoglobulin G4 subclass in non-small cell lung cancer. , 2013, Human pathology.

[106]  L. Chen,et al.  Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells , 2013, Cancer Gene Therapy.

[107]  Benjamin Haibe-Kains,et al.  CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. , 2013, The Journal of clinical investigation.

[108]  F. Nestle,et al.  IgG4 subclass antibodies impair antitumor immunity in melanoma , 2013 .

[109]  V. Sondak,et al.  12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy? , 2012, Scientific Reports.

[110]  P. Kuo,et al.  The tumor microenvironment. , 2012, Surgical oncology.

[111]  J. J. van den Oord,et al.  Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. , 2012, Cancer research.

[112]  J. Girard,et al.  Tumor high endothelial venules (HEVs) predict lymphocyte infiltration and favorable prognosis in breast cancer , 2012, Oncoimmunology.

[113]  H. Hammad,et al.  Tertiary lymphoid organs in infection and autoimmunity , 2012, Trends in Immunology.

[114]  P. Watson,et al.  CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27− Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer , 2012, Clinical Cancer Research.

[115]  P. Allavena,et al.  Tertiary Intratumor Lymphoid Tissue in Colo-Rectal Cancer , 2011, Cancers.

[116]  Jenna M. Sullivan,et al.  Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. , 2011, Immunity.

[117]  J. Girard,et al.  Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules , 2011, Nature.

[118]  P. Validire,et al.  Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. , 2011, Cancer research.

[119]  J. Tímár,et al.  Prognostic impact of B-cell density in cutaneous melanoma , 2011, Cancer Immunology, Immunotherapy.

[120]  T. Yeatman,et al.  Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. , 2011, The American journal of pathology.

[121]  R. Wersto,et al.  Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells. , 2011, Cancer research.

[122]  R. Lai,et al.  Survival in rectal cancer is predicted by T cell infiltration of tumour‐associated lymphoid nodules , 2010, Clinical and experimental immunology.

[123]  R. Écochard,et al.  Chronic Rejection Triggers the Development of an Aggressive Intragraft Immune Response through Recapitulation of Lymphoid Organogenesis , 2010, The Journal of Immunology.

[124]  L. Coussens,et al.  Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity , 2010, Cancer and Metastasis Reviews.

[125]  T. Tedder,et al.  B Cells Are Required for Optimal CD4+ and CD8+ T Cell Tumor Immunity: Therapeutic B Cell Depletion Enhances B16 Melanoma Growth in Mice , 2010, The Journal of Immunology.

[126]  A. Manzo,et al.  Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: from inflammation to autoimmunity and tissue damage/remodeling , 2010, Immunological reviews.

[127]  M. Willart,et al.  Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus–infected mice , 2009, The Journal of experimental medicine.

[128]  T. Douglas,et al.  Inducible Bronchus-Associated Lymphoid Tissue Elicited by a Protein Cage Nanoparticle Enhances Protection in Mice against Diverse Respiratory Viruses , 2009, PloS one.

[129]  D. Green,et al.  Immunogenic and tolerogenic cell death , 2009, Nature Reviews Immunology.

[130]  C. Tato,et al.  Lymphoid tissue inducer–like cells are an innate source of IL-17 and IL-22 , 2009, The Journal of experimental medicine.

[131]  E. Tartour,et al.  Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  C. Ware.  Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways , 2008, Immunological reviews.

[133]  T. Randall,et al.  Ectopic lymphoid tissues and local immunity. , 2008, Seminars in immunology.

[134]  Zhao-You Tang,et al.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  Noriaki Okamoto,et al.  Artificial lymph nodes induce potent secondary immune responses in naive and immunodeficient mice. , 2007, The Journal of clinical investigation.

[136]  J. Tímár,et al.  Density of DC-LAMP+ mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor , 2007, Cancer Immunology, Immunotherapy.

[137]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  R. Strieter,et al.  Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. , 2006, Cancer research.

[139]  Peter Carmeliet,et al.  VEGF as a Key Mediator of Angiogenesis in Cancer , 2005, Oncology.

[140]  Takeshi Watanabe,et al.  Generation of a synthetic lymphoid tissue–like organoid in mice , 2004, Nature Biotechnology.

[141]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[142]  Jason G. Cyster,et al.  Overlapping Roles of CXCL13, Interleukin 7 Receptor α, and CCR7 Ligands in Lymph Node Development , 2003, The Journal of experimental medicine.

[143]  R. Mebius.  Organogenesis of lymphoid tissues , 2003, Nature reviews. Immunology.

[144]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[145]  T. Cupedo,et al.  The role of CD45+CD4+CD3– cells in lymphoid organ development , 2002, Immunological reviews.

[146]  J. Cyster,et al.  Differing Activities of Homeostatic Chemokines CCL19, CCL21, and CXCL12 in Lymphocyte and Dendritic Cell Recruitment and Lymphoid Neogenesis1 , 2002, The Journal of Immunology.

[147]  K. Tamada,et al.  The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. , 2001, The Journal of clinical investigation.

[148]  J. Mulé,et al.  The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. , 2001, Cancer research.

[149]  J. Becker,et al.  Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. , 2001, Immunity.

[150]  Chris A. Benedict,et al.  The Lymphotoxin-β Receptor Is Necessary and Sufficient for LIGHT-mediated Apoptosis of Tumor Cells* , 2000, The Journal of Biological Chemistry.

[151]  J. Fjell,et al.  Lymphoid tissue homing chemokines are expressed in chronic inflammation. , 2000, The American journal of pathology.

[152]  J. Nyhus,et al.  B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion , 2000, Cancer Immunology, Immunotherapy.

[153]  Scott F. Smith,et al.  Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. , 1994, Science.

[154]  Holger Moch,et al.  Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. , 2018, Cancer research.

[155]  L. A. Antón Aparicio,et al.  Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer , 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[156]  T. Blankenstein,et al.  B cells inhibit induction of T cell-dependent tumor immunity , 1998, Nature Medicine.